Quadrature Capital Ltd Acquires Shares of 12,753 Cencora, Inc. (NYSE:COR)

Quadrature Capital Ltd bought a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,753 shares of the company's stock, valued at approximately $2,870,000.

A number of other institutional investors have also recently bought and sold shares of COR. New Millennium Group LLC acquired a new stake in Cencora during the 2nd quarter worth $26,000. MFA Wealth Advisors LLC bought a new position in shares of Cencora during the second quarter worth $30,000. Concord Wealth Partners bought a new position in shares of Cencora during the third quarter worth $30,000. SYSTM Wealth Solutions LLC bought a new position in shares of Cencora during the second quarter worth $36,000. Finally, Ashton Thomas Securities LLC bought a new position in shares of Cencora during the third quarter worth $41,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. The trade was a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 93,018 shares of company stock worth $22,478,942 in the last ninety days. Insiders own 15.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on COR. Leerink Partners reduced their price target on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research report on Monday, October 7th. Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Robert W. Baird lifted their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Finally, Bank of America reaffirmed a "neutral" rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and a consensus price target of $276.80.

Cencora Stock Down 0.4 %

NYSE:COR traded down $0.99 on Friday, hitting $243.32. 1,199,807 shares of the company's stock were exchanged, compared to its average volume of 1,389,951. The firm has a 50-day moving average price of $237.12 and a 200-day moving average price of $233.34. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. Cencora, Inc. has a 52 week low of $195.83 and a 52 week high of $253.27. The company has a market cap of $47.03 billion, a P/E ratio of 32.40, a price-to-earnings-growth ratio of 1.66 and a beta of 0.45.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This is a positive change from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. Cencora's payout ratio is currently 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.